Skip to main content

Table 2 Pharmacokinetic parameters of LZD after intravenous (i.v.) and oral (p.o.) administration with and without RFP

From: Effect of coadministration of rifampicin on the pharmacokinetics of linezolid: clinical and animal studies

   

Control

with RFP

i.v.

AUC0–12

μg/mL ▪ h

232 ± 61

194 ± 54

Cmax

μg/mL

72.5 ± 17.8

65.9 ± 15.2

ke

h−1

0.292 ± 0.041

0.329 ± 0.048

t1/2

h

2.41 ± 0.33

2.14 ± 0.29

CLtot

L/h/kg

0.210 ± 0.064

0.253 ± 0.078

Vd

L/kg

0.693 ± 0.156

0.758 ± 0.262

p.o.

AUC0–12

μg/mL ▪ h

280 ± 64

145 ± 103*

Cmax

μg/mL

48.0 ± 18.1

22.1 ± 12.1*

F

%

88.3 ± 20.1

45.8 ± 32.4*

  1. Values are mean ± SD of three to six rats. *p < 0.05
  2. AUC0–12 area under the concentration-time curve from time 0 to 12 h, Cmax maximum concentration, ke elimination rate constant, t1/2 half-life, CLtot total clearance, Vd volume of distribution, F bioavailability
Back to article page

Journal of Pharmaceutical Health Care and Sciences

ISSN: 2055-0294

Contact us